Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
Caribou Biosciences to Present at Upcoming Investor Conferences
04:00pm, Wednesday, 20'th Oct 2021
BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurw
Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors
04:05pm, Wednesday, 29'th Sep 2021
BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed
Caribou Biosciences to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
04:05pm, Monday, 27'th Sep 2021
BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haur
Caribou Biosciences Announces Publication of Data Demonstrating High Specificity Genome Editing with its Proprietary chRDNA Technology
04:05pm, Thursday, 02'nd Sep 2021
Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications
Caribou Biosciences Appoints Nancy Whiting, Pharm.D., to its Board of Directors
04:00pm, Wednesday, 25'th Aug 2021
BERKELEY, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that it has appo
Caribou Biosciences Aims For $255 Million IPO
01:48pm, Thursday, 22'nd Jul 2021
Caribou Biosciences has filed proposed terms for a $255 million IPO. The firm is developing hybrid CRISPR-Cas9-derived gene therapies for various cancers.
Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M
05:16am, Sunday, 11'th Jul 2021
Caribou Bioscience: Gene Editing Pioneer Files IPO To Raise $100M
Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood Cancer
01:18pm, Friday, 02'nd Jul 2021
In a filing with SEC on Thursday, Caribou Biosciences (NASDAQ: CRBU) is penciling in a $100 million initial public offering. The firm expects that its new shares will trade on the NASDAQ under the
